The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases

Area of Science:

• Immunology
• Rheumatology
• Clinical Diagnostics

Background:

• Rheumatoid arthritis (RA) diagnosis relies on clinical features, with limited early laboratory support before 1998.
• Rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were primary diagnostic and monitoring tools.
• Early RA diagnosis is challenging due to insufficient clinical criteria in the initial disease stages.

Purpose of the Study:

• To introduce anti-cyclic citrullinated peptide (anti-CCP) antibody as a novel serological marker for rheumatoid arthritis.
• To highlight the diagnostic accuracy and early detection capabilities of anti-CCP antibodies in RA.
• To explore the prognostic value of anti-CCP antibody titers in predicting treatment outcomes.

Main Methods:

• Detection of specific antibodies interacting with synthetic peptides containing citrulline.
• Evaluation of anti-CCP antibody specificity and sensitivity for RA diagnosis.
• Correlation of anti-CCP antibody titers with disease prognosis and response to disease-modifying antirheumatic drugs (DMARDs) and biological therapies.

Main Results:

• A high percentage of RA patients exhibit anti-CCP antibodies, demonstrating 98% specificity for RA.
• Anti-CCP antibodies are detectable early in RA, often preceding the onset of characteristic clinical manifestations.
• The presence or absence of anti-CCP antibodies effectively differentiates RA from other rheumatic conditions.

Conclusions:

• Anti-CCP antibody testing represents a significant advancement in the early and accurate diagnosis of rheumatoid arthritis.
• This marker aids in distinguishing RA from other rheumatic diseases and offers prognostic insights.
• With improved sensitivity, anti-CCP antibody testing is poised for widespread adoption in routine clinical practice for RA management.